|
|
|
BMY Forecast
Recent BMY Price |
|
BMY Forecast Price |
$43.70 |
+23.32% |
$53.89 |
As of 2024-05-03
Recent BMY Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
4 |
4 |
4 |
5 |
Buy ratings: |
1 |
1 |
1 |
1 |
Hold ratings: |
16 |
16 |
16 |
15 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
1 |
1 |
1 |
1 |
Average rating: |
2.65 |
2.65 |
2.65 |
2.56 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the Bristol Myers Squibb Co. forecast (traded under symbol BMY) for one year forward price target at the top of this page, we have presented the average BMY forecast for forward target price across the 18 analysts covering BMY, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median BMY forecast price target (median being the middle where half of analysts had a higher BMY forecast and half had a lower BMY forecast, which is a different metric than the average or mean) was $53.5 as of 2024-05-03, while the
highest BMY forecast in the analyst group was $69.0, and the lowest BMY forecast in the analyst group was
$37.0, with a standard deviation of $8.976. Get the latest Zacks research report on BMY — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
|
|
|
Hold (2.35 out of 4)
7th percentile
|
PARTNER NEWS:Fri, May 3, 3:08 AM, Zacks
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Thu, May 2, 8:02 AM, Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
|
|